Results 71 to 80 of about 2,655 (208)

Safety and efficacy of galcanezumab in chronic and episodic migraine patients: a systematic review and meta-analysis of randomized controlled trials

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Background The humanized monoclonal antibody galcanezumab is an anti-calcitonin-gene-related-peptide (CGRP) and frequently used for migraine prevention. However, the literature revealed limited data with conflicting results. This study aims to assess the
Mohamed Sayed Zaazouee, Rokaya Y. Ebrahim, Ghaida’a Al-araj, Ibram Zaki, Ahmed Saad, Abdullah Mohamed Farhat, Mustafa Hussein Ali, Mohamed Elshennawy, Omar Khaled Fahmy Fawy, Hadi F. Ahmed, Ziad Alahmad, Eman Ayman Nada, Reem I. Abo-Hamra, Ahmed Bostamy Elsnhory, Mohammed Eleyan, Hazem AbuEl-Enien, Rasha Abdo Elromely, Yossef Hassan AbdelQadir, Jaffer Shah, Alaa Ahmed Elshanbary   +19 more
doaj   +1 more source

MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study

European Journal of Neurology, Volume 33, Issue 4, April 2026.
Treatment response to anti‐CGRP medications for migraine is typically defined as a ≥ 50% reduction in monthly migraine days. However, the use of patient‐reported outcome measures (such as MIDAS and HIT‐6) has been proposed as alternative options.
Janu Thuraiaiyah, Rune Häckert Christensen, Haidar M. Al‐Khazali, Messoud Ashina, Zaza Katsarava, Håkan Ashina   +5 more
wiley   +1 more source

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Neurology and Therapy, 2023
Introduction There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention.
Todd J. Schwedt, Tina M. Myers Oakes, James M. Martinez, Bert B. Vargas, Hitendra Pandey, Eric M. Pearlman, Diane R. Richardson, Oralee J. Varnado, Michael Cobas Meyer, Peter J. Goadsby   +9 more
doaj   +1 more source

Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review [PDF]

, 2022
A significant proportion of patients exhibit sub-optimal response to the standard treatment of acute migraine such as triptans and NSAIDs. Even the conventional preventive therapies (e.g.
Ahsan, Marya, Mallick, Ayaz Khurram
core   +2 more sources

Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry‐Based Real‐World Study

European Journal of Neurology, Volume 33, Issue 4, April 2026.
ABSTRACT Background Recent post‐marketing studies have indicated a possible association between anti‐CGRP receptor monoclonal antibodies (anti‐CGRP‐mAbs) used for migraine prophylaxis and an increased risk of hypertension (HT). Methods We performed a retrospective real‐world exploratory study, including individuals with a confirmed diagnosis of ...
Christian Lampl, Reem Suliman, Viktoria Tischler‐Strasser, Antoinette MaassenVanDenBrink, Taoufik Alsaadi   +4 more
wiley   +1 more source

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review

Saudi Journal of Medicine and Medical Sciences, 2023
Migraine is a potentially disabling disorder, yet it remains underdiagnosed and undertreated. The release of the neuropeptide calcitonin gene-related peptide (CGRP) in the trigemino-cerebrovascular system plays a vital role in the evolution of migraine ...
Suruchi Aditya, Aditya Rattan
doaj   +1 more source

The Relevance of Crystal Clear and Unclear Days to Evaluate Residual Interictal Burden in Patients With Migraine Treated With CGRP Monoclonal Antibodies

European Journal of Neurology, Volume 33, Issue 4, April 2026.
ABSTRACT Background Although treatment goals in migraine prevention have moved beyond the benchmark of a 50% reduction in monthly attacks, residual disease burden is still evaluated based on residual headache frequency. However, migraine‐related symptoms can persist despite headache freedom, leading to so‐called unclear days that may meaningfully ...
Marcello Silvestro, Ilaria Orologio, Raffaele Ornello, Francesca Trojsi, Alessandro Tessitore, Simona Sacco, Antonio Russo   +6 more
wiley   +1 more source

Safety and Efficacy of Apixaban vs Rivaroxaban: In Nonvalvular Atrial Fibrillation [PDF]

, 2023
Nonvalvular atrial fibrillation, the most common cardiac arrhythmia in developed countries, warrants anticoagulation for stroke prevention. Updated guidelines recommend direct oral anticoagulants (DOACs) over historically used warfarin.
DeWitt, Cody
core   +1 more source

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 846-858, April 2026.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study

Toxins
Background: Chronic migraine (CM) is a disabling and hard-to-treat condition, associated with high disability and high cost. Among the preventive treatments, botulinum toxin A (BoNT-a) and monoclonal antibodies against the calcitonin gene-related protein
Danilo Antonio Montisano, Riccardo Giossi, Mattia Canella, Claudia Altamura, Marilena Marcosano, Fabrizio Vernieri, Alberto Raggi, Licia Grazzi   +7 more
doaj   +1 more source